SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication

Montezano, A. C. et al. (2023) SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication. Scientific Reports, 13, 14086. (doi: 10.1038/s41598-023-41115-3) (PMID:37640791) (PMCID:PMC10462711)

[img] Text
317635.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

COVID-19, caused by SARS-CoV-2, is a respiratory disease associated with inflammation and endotheliitis. Mechanisms underling inflammatory processes are unclear, but angiotensin converting enzyme 2 (ACE2), the receptor which binds the spike protein of SARS-CoV-2 may be important. Here we investigated whether spike protein binding to ACE2 induces inflammation in endothelial cells and determined the role of ACE2 in this process. Human endothelial cells were exposed to SARS-CoV-2 spike protein, S1 subunit (rS1p) and pro-inflammatory signaling and inflammatory mediators assessed. ACE2 was modulated pharmacologically and by siRNA. Endothelial cells were also exposed to SARS-CoV-2. rSP1 increased production of IL-6, MCP-1, ICAM-1 and PAI-1, and induced NFkB activation via ACE2 in endothelial cells. rS1p increased microparticle formation, a functional marker of endothelial injury. ACE2 interacting proteins involved in inflammation and RNA biology were identified in rS1p-treated cells. Neither ACE2 expression nor ACE2 enzymatic function were affected by rSP1. Endothelial cells exposed to SARS-CoV-2 virus did not exhibit viral replication. We demonstrate that rSP1 induces endothelial inflammation via ACE2 through processes that are independent of ACE2 enzymatic activity and viral replication. We define a novel role for ACE2 in COVID-19- associated endotheliitis.

Item Type:Articles
Additional Information:Tis work was supported by grants from the Wellcome Trust (204820/Z/16/Z; 206369/Z/17/Z) and the British Heart Foundation (BHF) (RG/13/7/30099; RE/13/5/30177). R.M.T. was supported by a British Heart Foundation Chair Award (CH/12/4/29762). Montezano was supported through a Walton Fellowship in Cardiovascular Medicine.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Samji, Dr Sheon and Beattie, Mrs Wendy and Palmarini, Professor Massimo and Montezano, Dr Augusto and Touyz, Professor Rhian and Neves, Dr Karla and Thomson, Mrs Jacqueline and Herder, Dr Vanessa and Szemiel, Dr Agnieszka and McFarlane, Mr Steven
Authors: Montezano, A. C., Camargo, L. L., Mary, S., Neves, K. B., Rios, F. J., Stein, R., Lopes, R. A., Beattie, W., Thomson, J., Herder, V., Szemiel, A. M., McFarlane, S., Palmarini, M., and Touyz, R.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Scientific Reports
Publisher:Nature Research
ISSN:2045-2322
ISSN (Online):2045-2322
Copyright Holders:Copyright: © The Author(s) 2023
First Published:First published in Scientific Reports 13: 14086
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
173707Institutional Strategic Support Fund (2016)Anna DominiczakWellcome Trust (WELLCOTR)204820/Z/16/ZSchool of Cardiovascular & Metabolic Health
301049Host determinants of disease outcomes in arboviral infectionsMassimo PalmariniWellcome Trust (WELLCOTR)206369/Z/17/ZSII - Virology
167932Vascular Noxs as therapeutic targets and biomarkers in hypertensionRhian TouyzBritish Heart Foundation (BHF)RG/13/7/30099School of Cardiovascular & Metabolic Health
190814BHF centre of excellenceRhian TouyzBritish Heart Foundation (BHF)RE/13/5/30177School of Cardiovascular & Metabolic Health
300689Vascular Noxs as therapeutic targets and biomarkers in hypertensionRhian TouyzBritish Heart Foundation (BHF)CH/12/4/29762SCMH - Cardiovascular & Metabolic Health